Quetiapine Teva

/ Abic

Adults
Treatment of schizophrenia: the total daily dose for the first 4 days of therapy is 50 mg (Day 1), 100 mg (Day 2), 200 mg (Day 3) and 300 mg (Day 4). From Day 4 onwards, the dose should be titrated to the usual effective dose range of 300 to 450 mg/day. Depending on the clinical response and tolerability of the individual patient, the dose may be adjusted within the range 150 to 750 mg/day.
Manic episodes associated with bipolar disorder: as mono-therapy or as adjunct therapy to mood stabilizers, the total daily dose for the first four days of therapy is 100 mg (Day 1), 200 mg (Day 2), 300 mg (Day 3) and 400 mg (Day 4). Further dosage adjustments up to 800 mg per day by Day 6 should be in increments of no greater than 200 mg per day. The dose may be adjusted depending on clinical response and tolerability of the individual patient, within the range of 200 to 800 mg per day. The usual effective dose is in the range of 400-800 mg per day.
Depressive episodes in bipolar disorder: Once daily at bedtime. Total daily dose for the first four days of therapy is 50 mg (Day 1), 100 mg (Day 2), 200 mg (Day 3) and 300 mg (Day 4). The recommended daily dose is 300 mg. Depending on the patient’s response quetiapine may be titrated up to 600 mg daily. Antidepressant efficacy was demonstrated at 300 mg and 600 mg/day, however no additional benefit was seen in the 600 mg group above 300 mg daily during short-term treatment. When treating depressive episodes in bipolar disorder, treatment should be prescribed by physicians experienced in treating bipolar disorder.
Elderly: Use with caution in the elderly, especially during the initial dosing period. Efficacy and safety has not been evaluated in patients over 65 years with depressive episodes in the framework of bipolar disorder.
Children & Adolescents: The safety and efficacy has not been evaluated in children and adolescents.

Indicated for the treatment of schizophrenia. Treatment of manic episodes associated with bipolar disorder. Treatment of major depressive episodes in bipolar disorders.

Hypersensitivity to the active substance or to any of the excipients. Concomitant administration of cytochrome P450 3A4 inhibitors, such as HIV-protease inhibitors, azole-antifungal agents, erythromycin, clarithromycin and nefazodone.

Renal Impairment: Dosage adjustment is not necessary in patients with renal impairment.
Hepatic Impairment: Use with caution in patients with known hepatic impairment, especially during the initial dosing period. Patients with known hepatic impairment should be started with 25 mg/day. The dosage should be increased daily with increments of 25 – 50 mg/day until an effective dosage, depending on the clinical response and tolerability of the individual patient is reached.